TuHURA Biosciences, Inc.

TuHURA Biosciences, Inc. is a Phase 3 immuno-oncology company dedicated to developing novel technologies and therapeutics aimed at overcoming primary and acquired resistance to existing cancer immunotherapies. Headquartered in Tampa, Florida, the company focuses on addressing the common reasons why cancer immunotherapies may fail or cease to be effective in many patients. [5, 6, 8, 12, 13, 14, 15, 16, 19]

The company's pipeline includes three distinct technological platforms. Its lead product candidate, IFx-2.0, is an innate immune agonist currently in a Phase 3 registration trial for advanced or metastatic Merkel Cell Carcinoma, designed to overcome primary resistance to checkpoint inhibitors. Additionally, TuHURA Biosciences is developing TBS-2025, a VISTA inhibiting monoclonal antibody acquired through its merger with Kineta Inc., which is progressing into Phase 1b/2 development for mutNPM1 r/r Acute Myeloid Leukemia (AML). The company also leverages its Delta Opioid Receptor (DOR) technology to create first-in-class, bi-specific, bi-functional antibody drug conjugates (ADCs) and antibody peptide conjugates (PDCs) that target Myeloid Derived Suppressor Cells (MDSCs) to mitigate immune-suppressing effects within the tumor microenvironment. [5, 6, 9, 12, 13, 14, 15, 16, 17, 18]

Recent developments include the announcement of a $50 million credit facility and royalty transaction in April 2026, extending its anticipated cash runway into 2028. TuHURA Biosciences also recently appointed Amanda Garofalo as Senior Vice President of Clinical Operations and announced that Dr. Craig Tendler will lead its VISTA program. The company regained compliance with Nasdaq's minimum bid price requirement in February 2026 and filed an Investigational New Drug Application for TBS-2025. Dr. James Bianco serves as the President and Chief Executive Officer. [2, 3, 4, 9, 14, 21]